SynthesisOral diseases2026
Clinicopathologic Analysis of Sarcomas in the Oral and Maxillofacial Region: A Systematic Review.
Synthesis in Oral diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to systematically review primary sarcomas in the oral and maxillofacial region, focusing on patient demographics and sarcoma-specific characteristics, including clinical presentation, histopathology, treatment approaches, outcomes, and survival rates. MATERIALS AND
methodsA systematic review was conducted in accordance with PRISMA 2020 guidelines and based on the PECOS framework, including observational studies on primary oral and maxillofacial sarcomas. An electronic search in five databases identified eligible studies, and outcomes were analyzed via Kaplan-Meier and Cox regression.
resultsThe review included 35 studies comprising 687 cases of sarcomas in the oral and maxillofacial region. The mean patient age was 35.26 years, with a slight male predominance. Lesions predominantly involved the mandible, with osteosarcoma being the most common histological subtype. Multimodal treatment was most frequent. Of 616 patients with survival data, 58.1% were alive at analysis. The overall 5-year survival and disease-free survival rates were 54.3% and 60.4%, respectively. Factors such as age, histological type, T classification, stage grouping, surgical margins, local recurrence, and distant metastases significantly influenced survival (p < 0.05).
conclusionThis study provides a comprehensive review of oral and maxillofacial sarcomas, offering data to understand the clinicopathological characteristics of these lesions, helping to improve their diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.